Schedule 1: replaced, on 25 October 2018, by regulation 4 of the Medicines Amendment Regulations 2018 (LI 2018/179).
Every reference to a medicine in this schedule applies whether the medicine is synthetic in origin or is from biological or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are—
•
preparations and admixtures containing any proportion of any substance listed in this schedule:
•
salts and esters of any substance listed in this schedule:
•
preparations or extracts of biological materials listed in this schedule:
•
salts or oxides of elements listed in this schedule.
Unless specific reference is made otherwise, every reference to a medicine in this schedule applies,—
•
if the medicine is an injection or eye preparation, to any concentration of that medicine; and
•
if the medicine is not an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol, or element unless specifically stated otherwise.
Part 1 Prescription medicines
Amending or replacing this Part may affect designated prescriber regulations under section 105(1)(q) of the Act.
11
Abrus precatorius; at all strengths
21
Acetylcholine; except in medicines containing 1 milligram or less per litre or per kilogram
22
Acetylcysteine; for injection or inhalation
24
Acetylmethyldimethyloximidophenylhydrazine
26
Aciclovir; except when specified elsewhere in this schedule
32
Aconitum spp; except when specified elsewhere in this schedule
35
Adapalene; except in medicines containing 1 milligram or less per millilitre or gram and when supplied by a pharmacist in a pack containing not more than 30 grams for the treatment of comedo, popular, and pustular acne (acne vulgaris) of the face, chest, or back
42
Adrenal extract; except for dermal use in medicines containing 0.02% or less of ketosteroids
43
Adrenaline; in medicines containing more than 1%
44
Adrenocortical hormones; except adrenal extract for dermal use containing 0.02% or less of ketosteroids
52
Albumin; except human albumin
54
Alclometasone; except when specified elsewhere in this schedule
55
Alcohol; for injection in medicines containing more than 20%
58
Aldosterone; except in medicines containing 10 micrograms or less per litre or per kilogram
73
Allylisopropylacetylurea; at all strengths
78
Alpha1-proteinase inhibitor
93
Amethocaine; except when specified elsewhere in this schedule; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
104
Aminophenazone; at all strengths
105
Aminophylline; except when specified elsewhere in this schedule
119
Amorolfine; except when specified elsewhere in this schedule; except in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
128
Amygdalin; at all strengths
136
Anchusa officinalis; at all strengths
137
Ancrod and its immunoglobulin antidote
138
Androgenic and anabolic steroidal agents
149
Antazoline; except for ophthalmic use
150
Antibiotic substances; except when specified elsewhere in this schedule
152
Antihistamines; except when specified elsewhere in this schedule
153
Antimony; except in medicines containing 1 milligram or less per litre or per kilogram
159
Apomorphine; except in medicines containing 1 milligram or less per litre or per kilogram
167
Aristolochia spp; at all strengths
168
Aristolochic acid; at all strengths
170
Arsenic; except in medicines containing 1 milligram or less per litre or per kilogram
173
Articaine; except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council
177
Aspirin; except when specified elsewhere in this schedule; for injection; when combined with caffeine, paracetamol, or salicylamide
189
Atropa belladonna; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total solanaceous alkaloids per litre or per kilogram
190
Atropine; except when specified elsewhere in this schedule; except when used as an antidote in a device designed for self-injection; except in medicines containing 300 micrograms or less per litre or per kilogram
201
Azatadine; except when specified elsewhere in this schedule
203
Azelaic acid; except when specified elsewhere in this schedule
204
Azelastine; except when specified elsewhere in this schedule
221
Beclomethasone; except when specified elsewhere in this schedule
240
Benzocaine; except when specified elsewhere in this schedule
241
Benzodiazepine derivatives; except when specified elsewhere in this schedule
242
Benzodiazepines; except when specified elsewhere in this schedule
244
Benzoyl peroxide; except when specified elsewhere in this schedule
246
Benzydamine; except when specified elsewhere in this schedule
251
Beta carotene; in medicines containing more than 18 milligrams per recommended daily dose
253
Betaine; for the treatment of homocystinuria
265
Bifonazole; except when specified elsewhere in this schedule
266
Bilastine; except when specified elsewhere in this schedule
270
Bismuth; except for external use in medicines containing 3% or less
272
Bithionol; at all strengths
282
Boron, including borax and boric acid; except in medicines for internal use containing 6 milligrams or less per recommended daily dose; except in medicines for dermal use other than paediatric use containing 0.35% or less; except when present as an excipient
292
Brivaracetam (and its stereoisomers)
296
Brompheniramine; except when specified elsewhere in this schedule
300
Buclizine; except for oral use
301
Budesonide; except when specified elsewhere in this schedule
302
Bufexamac; except in suppositories; except for dermal use in medicines containing 5% or less
304
Buniodyl sodium; at all strengths
314
Butoconazole; except for vaginal use
316
Butyl aminobenzoate; except in medicines for dermal use containing 2% or less
322
Cacalia spp; at all strengths
324
Calcipotriol; except in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30 grams or 30 millilitres by a pharmacist to an adult with mild to moderate psoriasis previously diagnosed by a doctor
328
Calcium polystyrene sulphonate
348
Carbaryl; except for external use in medicines containing 2% or less
351
Carbenoxolone; except for external use
370
Cebaracetam (and its stereoisomers)
398
Cephaelis acuminata; except in medicines containing less than 0.2% of emetine
399
Cephaelis ipecacuanha; except in medicines containing less than 0.2% of emetine
407
Cetirizine; except when specified elsewhere in this schedule
411
Chloral hydrate; except for dermal use in medicines containing 2% or less
415
Chloramphenicol; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when specified elsewhere in this schedule
423
Chloroform; for anaesthesia; except when specified elsewhere in this schedule
429
Chlorpheniramine; except when specified elsewhere in this schedule
438
Cholera vaccine; except in the form of an oral liquid containing vibrio cholerae when sold in a pharmacy by a registered pharmacist
440
Choline salicylate; except in medicines containing 10% or less and in pack sizes of 15 grams or less
441
Chorionic gonadotrophin; except in pregnancy test kits
445
Ciclopirox; except when specified elsewhere in this schedule
450
Cimetidine; except when specified elsewhere in this schedule
452
Cinchocaine; for injection; for ophthalmic use; for external use in medicines containing more than 0.5%
465
Clemastine; except for oral use
471
Clioquinol; at all strengths
474
Clobetasone; except when specified elsewhere in this schedule
493
Clotrimazole; except when specified elsewhere in this schedule
500
Cocaine; except when specified elsewhere in this schedule
501
Codeine; except when specified elsewhere in this schedule
506
Colecalciferol; except in medicines containing 25 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations
511
Collagen; in injections or implants for tissue augmentation or cosmetic use
512
Collagenase clostridium histolyticum
514
Conium maculatum; at all strengths
521
Cortisone and other steroidal hormones of the adrenal cortex; except when specified elsewhere in this schedule; except adrenal extract for dermal use in medicines containing 0.02% or less of ketosteroids
522
Cotarnine; at all strengths
527
Crotalaria spp; at all strengths
528
Croton tiglium; except in medicines containing 1 milligram or less per litre or per kilogram
532
Cyclizine; except when specified elsewhere in this schedule
537
Cyclopentolate; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
545
Cynoglossum spp; at all strengths
546
Cyproheptadine; except for oral use
572
Datura spp; except for oral use when specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning
582
Dehydrochloromethyltestosterone
590
Deoxycholic acid; for injection; except for oral use
591
Deoxyribonuclease; except for external use
592
Dermatophagoides farina allergen extract
593
Dermatophagoides pteronyssinus allergen extract
599
Desloratadine; except for oral use
602
Desogestrel; except when supplied for oral contraception to women who meet the clinical and eligbility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
608
Dexchlorpheniramine; except when specified elsewhere in this schedule
611
Dextromethorphan; except when specified elsewhere in this schedule
615
Di-iodohydroxy quinoline; except when specified elsewhere in this schedule
616
Di-isopropylamine dichloroacetate
621
Dibrompropamidine; except for ophthalmic use
625
Diclofenac; in preparations for the treatment of solar keratosis; except when specified elsewhere in this schedule; except in preparations for topical use other than for the treatment of solar keratosis
641
Digoxin-specific antibody fragment
648
Dimenhydrinate; except when specified elsewhere in this schedule
652
Dimethindene; except for oral use
657
Dimiracetam (and its stereoisomers)
665
Diphemanil; except for dermal use
666
Diphenhydramine; except when specified elsewhere in this schedule
668
Diphenoxylate; except when specified elsewhere in this schedule
670
Diphtheria, tetanus and pertussis (acellular, component) vaccine; except when administered in a single dose to a person 18 years of age or over or to a pregnant woman aged 13 years or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
685
Doliracetam (and its stereoisomers)
701
Doxylamine; except when specified elsewhere in this schedule
707
Duboisia leichhardtii; except when specified elsewhere in this schedule
708
Duboisia myoporides; except when specified elsewhere in this schedule
715
Econazole; except when specified elsewhere in this schedule
719
Edetic acid; except in medicines containing 0.25% or less; except in contact lens preparations; except dicobalt edetate for the treatment of cyanide poisoning
733
Emetine; except in medicines containing 0.2% or less
761
Ergocalciferol; except in medicines containing 25 micrograms or less per recommended daily dose
770
Erysimum spp; except in medicines containing 1 milligram or less per litre or per kilogram
775
Esomeprazole; except when specified elsewhere in this schedule
783
Ethanolamine; for injection
785
Ether; for anaesthesia; except when specified elsewhere in this schedule
787
Ethinyloestradiol; except when supplied at a strength of 35 micrograms or less in combination with either levonorgestrel or norethisterone for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
796
Ethyl chloride; for inhalation
799
Ethylhexanediol; at all strengths
803
Etidronic acid; except in medicines for external use containing 1% or less
807
Etofenamate; except for external use
819
Factor VIII inhibitor bypassing fraction
820
Famciclovir; except when specified elsewhere in this schedule
821
Famotidine; except when specified elsewhere in this schedule
823
Farfugium japonicum; at all strengths
824
Fasoracetam (and its stereoisomers)
827
Felbinac; except for external use
829
Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist or oral health therapist registered with the Dental Council
842
Fexofenadine; except when specified elsewhere in this schedule
844
Fibrinolysin; except for external use
857
Fluconazole; except when specified elsewhere in this schedule
873
Fluorescein; for injection
874
Fluorides; for internal use in medicines containing more than 0.5 milligrams per dose unit except in medicines containing 15 milligrams or less per litre or per kilogram; except in parenteral nutrition replacement preparations; for external use in medicines containing more than 5.5 grams per litre or per kilogram except when supplied to a dental professional registered with the Dental Council
883
Flurbiprofen; except when specified elsewhere in this schedule
887
Fluticasone; except when specified elsewhere in this schedule
890
Folic acid; except when specified elsewhere in this schedule
891
Folinic acid; except when specified elsewhere in this schedule
892
Follicle-stimulating hormone; except in medicines containing 100 micrograms or less per litre or per kilogram
899
Fonturacetam (and its stereoisomers)
946
Glutathione; for injection
947
Glyceryl trinitrate; for injection; for transdermal use; except in medicines containing 100 micrograms or less per litre or per kilogram
952
Gonadotrophic hormones; except when specified elsewhere in this schedule
959
Growth hormone releasing hormones
960
Growth hormone releasing peptide-6
961
Growth hormone releasing peptides
962
Guaifenesin; except when specified elsewhere in this schedule
970
Haemophilus influenzae vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
975
Haloperidol; except in medicines containing 1 milligram or less per litre or per kilogram
978
Halquinol; except for external use
979
Heliotropium spp; at all strengths
981
Heparins; except when present as an excipient; except for external use
985
Hexachlorophane; in medicines containing more than 3%; except when specified elsewhere in this schedule
988
Hexetidine; except for external use
993
Histamine; except in medicines containing 0.5% or less
995
Human chorionic gonadotrophin; except in pregnancy test kits
996
Human growth hormone secretagogues
997
Human papillomavirus vaccine
999
Hyaluronic acid; in injections or implants for tissue augmentation or cosmetic use
1003
Hydrocortisone; except when specified elsewhere in this schedule
1004
Hydrocyanic acid; except when specified elsewhere in this schedule
1007
Hydroquinone; except when specified elsewhere in this schedule
1015
Hylan polymer; in injections or implants for tissue augmentation or cosmetic use
1016
Hyoscine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram
1017
Hyoscine butylbromide; except when specified elsewhere in this schedule
1018
Hyoscyamine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram
1019
Hyoscyamus niger; except when specified elsewhere in this schedule
1020
Hypothalamic releasing factors
1021
Hypromellose; for injection; except in intraocular viscoelastic products
1027
Ibuprofen; except when specified elsewhere in this schedule
1035
Idoxuridine; except for dermal use in medicines containing 0.5% or less
1049
Indomethacin; except when specified elsewhere in this schedule
1053
Influenza and coryza vaccines; for injection; for nasal use
1054
Influenza vaccine; except when administered to a person 13 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
1057
Insulin-like growth factors; except when specified elsewhere in this schedule
1063
Ipecacuanha; except when specified elsewhere in this schedule
1065
Ipratropium; except for nasal use
1071
Iron; except when specified elsewhere in this schedule
1076
Isoconazole; except when specified elsewhere in this schedule
1083
Isopropamide; except when specified elsewhere in this schedule
1097
Japanese encephalitis vaccine
1098
Juniperus sabina; at all strengths
1103
Ketoconazole; except when specified elsewhere in this schedule
1104
Ketoprofen; except when specified elsewhere in this schedule
1106
Ketotifen; except for ophthalmic use in medicines containing 0.025% or less
1115
Lansoprazole; except when specified elsewhere in this schedule
1123
Lauromacrogols; for injection
1137
Leucovorin; for injection
1144
Levocabastine; except for nasal or ophthalmic use
1145
Levocetirizine; except for oral use
1149
Levonorgestrel; except when specified elsewhere in this schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
1152
Lidocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatrists Board or by a dental therapist or an oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule
1153
Ligularia dentata; at all strengths
1156
Lindane; except for external use in medicines containing 2% or less
1164
Lithium; except when specified elsewhere in this schedule; except when present as an excipient in dermal medicines containing 0.25% or less
1166
Lodoxamide; except in medicines for ophthalmic use
1170
Loperamide; except when specified elsewhere in this schedule
1174
Loratadine; except when specified elsewhere in this schedule
1179
Lovastatin; except when present as an unmodified, naturally occurring substance in a food that has not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches
1205
Meclozine; except when specified elsewhere in this schedule
1210
Mefenamic acid; except when specified elsewhere in this schedule
1215
Melanocyte stimulating compounds
1218
Melia azedarach; at all strengths
1222
Meningococcal vaccine; except when administered to a person 16 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
1234
Mepyramine; except when specified elsewhere in this schedule
1238
Mercurochrome; except when specified elsewhere in this schedule
1239
Mercury; except when specified elsewhere in this schedule
1261
Methdilazine; except for oral use
1270
Methoxamine; except when specified elsewhere in this schedule
1278
Methyl mercury; except in medicines containing 300 micrograms or less per litre or per kilogram
1279
Methyl salicylate; except for external use; except for internal use when present as an excipient in medicines containing 1.04% or less per dose form
1282
Methylene blue; for injection
1284
Methylhexanamine (1,3-dimethylamylamine (DMAA)); except when present as an unmodified, naturally occurring substance
1294
Metoclopramide; except when specified elsewhere in this schedule
1307
Miconazole; except when specified elsewhere in this schedule
1317
Minoxidil; except for dermal use in medicines containing 5% or less
1332
Mometasone; except when specified elsewhere in this schedule
1334
Monoclonal antibodies; except in pregnancy test kits
1339
Morphine; except when specified elsewhere in this schedule
1360
Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose
1363
Naproxen; except when specified elsewhere in this schedule
1370
Nebracetam (and its stereoisomers)
1391
Nicotine; except when specified elsewhere in the schedule; except in preparations for oromucosal or transdermal absorption; for nasal use except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner; in medicines other than for smoking cessation
1392
Nicotinic acid except nicotinamide; except when specified elsewhere in this schedule
1413
Nitrous oxide; when supplied for inhalation
1416
Nizatidine; except when specified elsewhere in this schedule
1419
Noopept (and its stereoisomers)
1427
Norethisterone; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
1435
Nux vomica; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine
1436
Nystatin; except when specified elsewhere in this schedule
1444
Oestradiol; except in medicines containing 10 micrograms or less per litre or per kilogram
1447
Oestrone; except in medicines containing 1 milligram or less per litre or per kilogram
1460
Omeprazole; except when specified elsewhere in this schedule
1463
Opium; except when specified elsewhere in this schedule
1465
Orlistat; except in medicines for weight control containing 120 milligrams or less per dose form
1470
Oseltamivir; except when specified elsewhere in this schedule
1483
Oxedrine; except in medicines containing 30 milligrams or less per recommended daily dose
1484
Oxetacaine; except for internal use
1485
Oxiconazole; except when specified elsewhere in this schedule
1486
Oxiracetam (and its stereoisomers)
1492
Oxybuprocaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
1499
Oxyphenisatin; at all strengths
1502
Oxytocin; except in medicines containing 1 microgram or less per litre or per kilogram
1511
Pancreatic enzymes; except in medicines containing 20 000 BP units or less of lipase activity
1515
Pantoprazole; except when specified elsewhere in this schedule
1517
Papaverine; for injection
1518
Paracetamol; except when specified elsewhere in this schedule
1528
Patent blue V; for injection when used in diagnostic procedures
1529
Patiromer sorbitex calcium
1544
Penciclovir; except when specified elsewhere in this schedule
1546
Pentaerythrityl tetranitrate
1553
Pentosan polysulfate sodium
1562
Permethrin; except in medicines containing 5% or less
1565
Pertussis (whooping cough) vaccine
1569
Phenacetin; except when present as an excipient
1571
Phenazone; except for external use
1579
Pheniramine; except when specified elsewhere in this schedule
1592
Phenylephrine; except when specified elsewhere in this schedule
1597
Pholcodine; except when specified elsewhere in this schedule
1598
Phosphodiesterase type 5 inhibitors; except when present as an unmodified, naturally occurring substance; except when specified elsewhere in this schedule
1605
Pilocarpine; except in medicines containing 0.025% or less
1628
Piroxicam; except for external use
1636
Pneumococcal vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1637
Podophyllotoxin; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 1%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
1638
Podophyllum emodi; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
1639
Podophyllum peltatum; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
1642
Polyacrylamide; in injections or implants for tissue augmentation or cosmetic use
1644
Polylactic acid; in injections or implants for tissue augmentation or cosmetic use
1646
Polysulfated glycosaminoglycans; for injection except in intraocular viscoelastic products
1675
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or an oral therapist registered with the Dental Council; except when specified elsewhere in this schedule
1684
Prochlorperazine; except when specified elsewhere in this schedule; except when sold for the treatment of nausea associated with emergency contraception by pharmacists or nurses accredited to sell levonorgestrel for emergency contraception
1685
Procyclidine; except for dermal use in medicines containing 5% or less
1686
Progesterone; except in medicines containing 1 milligram or less per litre or per kilogram
1692
Promethazine; except when specified elsewhere in this schedule
1695
Propamidine; except for ophthalmic use
1701
Propranolol; except in medicines containing 1 milligram or less per litre or per kilogram
1713
Proxymetacaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
1716
Pulmonaria spp; at all strengths
1720
Pyridoxal; except in medicines containing 200 milligrams or less per recommended daily dose
1721
Pyridoxamine; except in medicines containing 200 milligrams or less per recommended daily dose
1722
Pyridoxine; except in medicines containing 200 milligrams or less per recommended daily dose
1732
Quinine; except in medicines containing 50 milligrams or less per recommended daily dose
1743
Ranitidine; except when specified elsewhere in this schedule
1752
Recombinant human epidermal growth factor
1753
Recombinant varicella zoster virus glycoprotein E antigen
1786
Rizatriptan; except when specified elsewhere in this schedule
1790
Rolipram (and its stereoisomers)
1809
Sabadilla; except in preparations containing 10 milligrams or less of total alkaloids of schoenocaulon officinale per litre or per kilogram
1811
Safrole; for internal use except in medicines containing 0.1% or less
1820
Schoenocaulon officinale; except in preparations containing 10 milligrams or less of total alkaloids of schoenocaulon officinale per litre or per kilogram
1826
Selective androgen receptor modulators
1827
Seletracetam (and its stereoisomers)
1829
Selenium; except when specified elsewhere in this schedule; except for oral use in medicines containing 150 micrograms or less per recommended daily dose
1838
Sex hormones and all substances having sex hormone activity
1842
Sildenafil and its structural analogues; except sildenafil in medicines for oral use containing 100 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 12 solid dosage units for the treatment of erectile dysfunction in males aged 35–70 years by a registered pharmacist who has successfully completed a training programme endorsed by the Pharmaceutical Society of New Zealand Incorporated
1846
Silver sulfadiazine; except for external use in packs containing 50 grams or less
1854
Sodium cellulose phosphate; for internal use
1855
Sodium cromoglycate; except for nasal and ophthalmic use
1856
Sodium morrhuate; for injection
1859
Sodium phosphate; in oral laxative preparations
1860
Sodium polystyrene sulphonate
1861
Sodium tetradecyl sulphate; for injection
1862
Sodium zirconium cyclosilicate
1880
Staphylococcus aureus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1886
Stramonium; except for oral use when specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning
1887
Streptococcus beta-haemolyticus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1895
Strychnos spp; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine
1901
Sulconazole; except for dermal use
1902
Sulfacetamide; except for ophthalmic use in medicines containing 10% or less
1903
Sulfadiazine; except silver sulfadiazine for external use in pack sizes of 50 grams or less
1928
Sumatriptan; except when specified elsewhere in this schedule
1939
Tadalafil and its structural analogues
1946
Tanacetum vulgare; except in medicines containing 0.8% or less of oil of tansy
1968
Terbinafine; except when specified elsewhere in this schedule
1978
Testosterone; except in medicines containing 1 milligram or less per litre or per kilogram
1991
Theophylline; except when specified elsewhere in this schedule
2008
Thiourea; except in medicines containing 0.1% or less
2013
Thyrotrophin-releasing factor
2014
Thyroxine; except in medicines containing 10 micrograms or less per litre or per kilogram
2034
Tioconazole; except when specified elsewhere in this schedule
2063
Trametinib dimethyl sulfoxide
2078
Triamcinolone; except when specified elsewhere in this schedule
2083
Trichloroacetic acid; except for external use in medicines containing 12.5% or less for the treatment of warts other than anogenital warts
2085
Trichodesma africana; at all strengths
2094
Trimeprazine; except when specified elsewhere in this schedule
2096
Trimethoprim; except in medicines for oral use containing 300 milligrams or less per dose unit when sold in a pack of 3 solid dosage units to a woman aged 16–65 years for the treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the New Zealand College of Pharmacists’ training in the treatment of urinary tract infections
2101
Triparanol; at all strengths
2103
Triprolidine; except when specified elsewhere in this schedule
2106
Trometamol; for injection in medicines containing more than 3%
2107
Tropicamide; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
2111
Tryptophan; except in medicines containing 100 milligrams or less per recommended daily dose; except in parenteral nutrition replacement preparations
2127
Vaccines; except when specified elsewhere in this schedule
2137
Vardenafil and its structural analogues
2139
Varicella vaccine; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
2168
Vitamin A; except for internal use in medicines containing 3 milligrams or less of retinol equivalents per recommended daily dose; except in parenteral nutrition replacement preparations; except for external use in medicines containing 1% or less
2169
Vitamin D; except for external use; except for internal use in medicines containing 25 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations
2187
Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use when in medicines containing 5% or less; except in parenteral nutrition replacement preparations
2190
Zolmitriptan; except when specified elsewhere in this schedule
2194
Zoster immunoglobulin, human
Part 2 Restricted medicines
1
Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less
2
Alclometasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack
3
Aminophylline; for oral use in liquid form in medicines containing 2% or less
4
Amorolfine; for external use in medicines containing more than 0.25%
5
Aspirin; in slow-release forms; in enteric coated forms containing more than 300 milligrams per dose form
6
Azatadine; for oral use in adults and children over 2 years of age
7
Azelastine; in medicines for ophthalmic use containing 0.05% or less
8
Brompheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
10
Butoconazole; for vaginal use
11
Chloramphenicol; for ophthalmic use; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
12
Chlorbutol; except when specified elsewhere in this schedule
13
Chlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
14
Ciclopirox; for external use in medicines containing more than 2%; in preparations for application to the nails containing more than 8%
15
Cimetidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply
17
Clobetasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack
18
Clotrimazole; for vaginal use
19
Codeine; in medicines for oral use containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, for use as an analgesic and when sold in a pack of not more than 5 days’ supply, approved by the Minister or the Director-General for distribution as a restricted medicine
20
Cyclizine; for oral use other than in medicines used for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 6 dosage units; for oral use in medicines used for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
21
Cyproheptadine; for oral use
22
Dexchlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
23
Di-iodohydroxy quinoline; for vaginal use
24
Diclofenac; in solid dose form in medicines containing 25 milligrams or less and more than 12.5 milligrams per dose form in packs containing not more than 30 tablets or capsules
25
Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule
26
Dimethindene; for oral use
27
Diphenhydramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
29
Doxylamine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
30
Econazole; for vaginal use
32
Famciclovir; in divided solid dosage forms for oral use containing 500 milligrams or less for the treatment of recurrent herpes labialis when sold in the manufacturer’s original pack containing up to 3 dosage units
34
Fluconazole; for oral use in medicines that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack containing 150 milligrams or less as a single dose for the treatment of vaginal candidiasis
35
Fluorides; for external use in liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as restricted medicines; for external use in non-liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram, except in medicines containing 1.5 grams or less and more than 1 gram per litre or per kilogram; except when supplied to a dental professional registered with the Dental Council
36
Glucagon; except in medicines containing 100 micrograms or less per litre or per kilogram
37
Glyceryl trinitrate; for oral or sublingual use; for rectal use
38
Guaifenesin; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing more than 10 days’ supply but not more than 30 days’ supply; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply; except for oral use in medicines containing 2% or less or 200 milligrams or less per dose form
39
Haemophilus influenzae vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
40
Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except 5% or less by weight of aciclovir and in a quantity of 2 grams or less or 2 millilitres or less per container in adults and children 12 years of age and older; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack
41
Hyoscine butylbromide; for oral use in medicines containing not more than 20 milligrams per dose form and in packs containing not more than 10 tablets or capsules for the relief of muscle spasm of the gastrointestinal tract
42
Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units and that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack labelled for use by adults or children over 12 years of age
44
Isoconazole; for vaginal use
45
Ketoprofen; in solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets
46
Lansoprazole; in divided solid dosage forms for oral use containing 15 milligrams or less with a maximum daily dose of 15 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over for the relief of heartburn when sold in the manufacturer’s original pack containing not more than 14 dosage units
47
Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing not more than 1.5 milligrams
48
Macrogols; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures
49
Malathion; except for external use in medicines containing 2% or less
51
Meclozine; in a pack size of up to 10 dosage units for the treatment of insomnia
52
Mepyramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
53
Methdilazine; for oral use
54
Metoclopramide; when compounded with paracetamol in packs of not more than 10 tablets or capsules for the treatment of nausea associated with migraine
55
Miconazole; for the treatment of oral candidiasis; for vaginal use
56
Nicotinic acid except nicotinamide; in medicines containing 250 milligrams or less but more than 100 milligrams per dose form; except in medicines containing 100 milligrams or less per dose form
57
Nicotinyl alcohol; except in medicines containing 100 milligrams or less per dose form
58
Nystatin; for the treatment of oral candidiasis; for vaginal use
59
Orlistat; in medicines for weight control containing 120 milligrams or less per dose form
60
Oseltamivir; in solid dosage forms for oral use containing 75 milligrams in a pack size of up to 10 dosage units for the treatment or prophylaxis of influenza in adults and children aged 13 years and older who have been exposed to the influenza virus
61
Oxiconazole; for vaginal use
62
Pheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
63
Pneumococcal vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
64
Podophyllotoxin; for external use for the treatment of warts other than anogenital warts in medicines containing 1% or less and more than 0.5%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
65
Podophyllum emodi; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
66
Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
67
Prochlorperazine; in packs containing not more than 10 tablets or capsules for the treatment of nausea associated with migraine
68
Promethazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
69
Rizatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5 milligrams or less per wafer and when sold in a pack containing not more than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine
70
Salicylic acid; except in medicines for dermal use containing 40% or less
72
Sodium phosphate; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures
73
Sodium picosulphate; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures
74
Staphyloccocus aureus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
75
Stramonium; for oral use in liquid form; in solid dose form in medicines containing more than 0.3 milligrams per dose or more than 1.2 milligrams per recommended daily dose
76
Streptococcus beta-haemolyticus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
77
Sulfacetamide; for ophthalmic use in medicines containing 10% or less
78
Sumatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when in tablets containing 50 milligrams or less per tablet and when sold in a pack containing not more than 2 tablets that has received the consent of the Minister or the Director-General to its sale as a restricted medicine
79
Theophylline; in liquid form for oral use in medicines containing 2% or less
80
Tioconazole; for vaginal use
81
Triamcinolone; for buccal use in medicines containing 0.1% or less of triamcinolone acetonide and in pack sizes of 5 grams or less
82
Trimeprazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
83
Triprolidine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule
84
Zolmitriptan; in a pre-filled nasal spray device containing not more than 5 milligrams of zolmitriptan, for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms and when sold in a pack of not more than 2 devices approved by the Minister or the Director-General for distribution as a restricted medicine
Part 3 Pharmacy-only medicines
1
8-hydroxyquinoline and its non-halogenated derivatives; in medicines containing more than 1% of such substances; except for hydroxyquinoline sulphate for external use
2
Acetic acid and preparations containing more than 80% of acetic acid (CH3COOH); excluding its salts and derivatives
3
Acetylcysteine; for oral use in medicines containing more than 1 gram per recommended daily dose
4
Aciclovir; for external use for the treatment of herpes labialis except in medicines containing 5% or less and in tubes containing 10 grams or less
5
Aconitum spp; for oral use in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids; for dermal use in concentrations of 0.02% or less and in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids
6
Aloes; for internal use; except when obtained solely from the mucilaginous gel of the leaf
9
Amethocaine; for external use in medicines containing 10% or less and more than 2%; except in medicines for external use containing 2% or less
10
Amorolfine; in preparations for topical use; except in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
11
Antazoline; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
12
Atropa belladonna; for external use in medicines containing 0.03% or less of the alkaloids of belladonna; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of the alkaloids of belladonna or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of the alkaloids of belladonna
13
Atropine; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose; in medicines containing atropine sulphate for the treatment of organophosphorus poisoning either in packs of not more than 20 dose units containing 0.6 milligrams or less per dose unit or in injections in packs of not more than 5 vials containing 0.6 milligrams per millilitre; except when sold as an antidote in a device designed for self-injection from outlets licensed to sell organophosphorus poisons; except in medicines containing 300 micrograms or less per litre or per kilogram
14
Azelaic acid; for dermal use
15
Azelastine; in preparations for nasal use containing 0.15% azelastine hydrochloride or less; in topical eye preparations containing 0.05% or less
16
Beclomethasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) in a pack containing 200 actuations or less
17
Benzocaine; in preparations for topical use, other than eye drops, containing 10% or less of total anaesthetic substances except in dermal preparations containing 2% or less of total anaesthetic substances; in divided preparations containing 200 milligrams or less of total anaesthetic substances per dosage unit except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit
18
Benzoyl peroxide; for external use in medicines containing more than 5% and not more than 10%; except for medicines for external use containing 5% or less
19
Benzydamine; for external use except for oromucosal or topical use
21
Bifonazole; except when specified elsewhere in this schedule; except for dermal use in medicines for tinea pedis only or in shampoos containing 1% or less or when sold in practice by a podiatrist registered with the Podiatrists Board
22
Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria when sold in a pack containing not more than 30 dosage units
25
Brompheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing brompheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
26
Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) in a pack containing 200 actuations or less
27
Carbetapentane; except in medicines containing 0.5% or less
29
Cetirizine; for oral use except in divided solid dosage forms for oral use containing 10 milligrams or less of cetirizine hydrochloride per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply
31
Chlorbutol; in medicines containing 5% or less and more than 0.5%; except in medicines containing 0.5% or less
32
Chloroform; in medicines other than for anaesthesia containing more than 0.5%; except in medicines containing 0.5% or less
33
Chlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing chlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
34
Ciclopirox; for external use in medicines containing 2% or less except when for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; in preparations for application to the nails containing 8% or less
35
Cinchocaine; for external use in medicines containing 0.5% or less
37
Clotrimazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
38
Cocaine; in medicines for oral use, containing not more than 0.1% of cocaine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, and when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
39
Codeine; in medicines for oral use, containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, for the treatment of the symptoms of cough and cold and when sold in a pack of not more than 6 days’ supply, approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
41
Creosote; except in medicines containing 10% or less
42
Cresols; except in medicines containing 3% or less
43
Datura spp; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
44
Delphinium staphisagria; except in medicines containing 0.2% or less
45
Desloratadine; for oral use
46
Dexchlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing dexchlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
47
Dextromethorphan; in liquid form containing more than 0.25% or in solid dose form containing more than 15 milligrams per dose form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years; except in liquid form containing 0.25% or less in solid dose form containing 15 milligrams or less per dose form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams
48
Dibrompropamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
49
Diclofenac; in solid dose form in medicines containing 12.5 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 75 milligrams
50
Diphenoxylate; in liquid form containing in each millilitre not more than 0.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate; in solid dose form containing not more than 2.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate
51
Dimenhydrinate; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults or children over 2 years of age except when sold at a transport terminal or aboard a ship or an aircraft
52
Diphenhydramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing diphenhydramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or an aircraft
53
Doxylamine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing doxylamine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
54
Duboisia leichhardtii; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
55
Duboisia myoporides; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
56
Econazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
57
Esomeprazole; in oral preparations containing 20 milligrams or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply
59
Ether; in medicines containing more than 10%; except in medicines containing 10% or less
60
Etofenamate; for external use
61
Famotidine; for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply
62
Felbinac; for external use
63
Fexofenadine; for oral use except for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 5 days’ supply
64
Fluorides; for internal use in medicines containing 0.5 milligrams or less per dose unit; except in parenteral nutrition replacement preparations; for external use in liquid form in medicines containing 1 gram or less per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as pharmacy-only medicines except in medicines containing 220 milligrams or less per litre or per kilogram and in packs containing not more than 120 milligrams of total fluoride; except when supplied to any dental professional registered with the Dental Council; except in medicines containing 15 milligrams or less per litre or per kilogram
65
Flurbiprofen; in locally acting oromucosal preparations containing 10 milligrams or less per dosage unit
66
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose) in a pack containing 200 actuations or less
67
Folic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose; except for oral use in medicines containing 500 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations
68
Folinic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose; except for oral use in medicines containing 500 micrograms or less per recommended daily dose
69
Formaldehyde; except in medicines containing 5% or less
70
Gelsemium sempervirens; except in medicines containing 1 milligram or less per litre or per kilogram
72
Hexachlorophane; in medicines containing 3% or less but more than 0.75%; except in medicines containing 0.75% or less
73
Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 0.5% or less by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 0.5% or less by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or 12 suppositories or fewer per pack
74
Hydrocyanic acid; for oral use in packs containing 5 milligrams or less and more than 0.5 milligrams; except in medicines containing 1 microgram or less per litre or per kilogram; except for oral use in packs containing 0.5 milligrams or less
75
Hydroquinone; for external use in medicines containing 2% or less except in hair preparations containing 1% or less
76
Hyoscine; for transdermal use in medicines containing 2 milligrams or less of total solanaceous alkaloids per dose unit; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
77
Hyoscyamine; for external use in medicines containing 0.03% or less of total solanaceous alkaloids; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
78
Hyoscyamus niger; for oral use in liquid form in medicines containing 0.03% or less (300 micrograms or less of total solanaceous alkaloids per litre or per kilogram) and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose except in packs containing 30 micrograms or less of total solanaceous alkaloids
79
Ibuprofen; for oral use in liquid form with a recommended daily dose of not more than 1.2 grams for the relief of pain and reduction of fever or inflammation when sold in the manufacturer’s original pack containing not more than 8 grams; for oral use in solid dose form containing not more than 200 milligrams per dose form and with a recommended daily dose of not more than 1.2 grams when sold in the manufacturer’s original pack containing not more than 100 dose units; except in divided solid dosage forms for oral use containing 200 milligrams or less per dose form with a recommended daily dose of not more than 1.2 grams and when sold in the manufacturer’s original pack containing not more than 25 dose units; except for external use
81
Indomethacin; for external use in medicines containing 1% or less; except in medicines containing 1 milligram or less per litre or per kilogram
82
Iodine; except for external use in medicines containing 2.5% or less; for internal use in medicines containing less than 300 micrograms per recommended daily dose
83
Ipecacuanha; in medicines containing 0.2% or less of emetine and 40 micrograms or more of ipecacuanha alkaloids per recommended dose for the treatment of the symptoms of cough and cold in children aged 6–12 years; except in medicines containing less than 40 micrograms of ipecacuanha alkaloids per recommended dose for the treatment of the symptoms of cough and cold in children aged 6–12 years
84
Ipomoea spp; except ipomoea batatas
85
Ipratropium; for nasal use
86
Iron; for oral use either in medicines containing more than 24 milligrams per recommended daily dose or in medicines containing more than 5 milligrams per dose unit and more than 750 milligrams of iron per pack; except in parenteral nutrition replacement preparations; except for oral use in medicines containing 24 milligrams or less per recommended daily dose in medicines containing not more than 5 milligrams per dose unit; except for oral use in medicines containing 24 milligrams or less per recommended daily dose in medicines containing more than 5 milligrams per dose unit in packs containing not more than 750 milligrams of iron
87
Isoconazole; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board
88
Isopropamide; for dermal use in preparations containing 2% or less
90
Ketoconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for treatment of the scalp containing 1% or less
91
Ketotifen; for ophthalmic use in medicines containing 0.025% or less except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
92
Leucovorin; in medicines containing more than 500 micrograms per recommended daily dose
93
Levocabastine; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
94
Levocetirizine; for oral use
95
Lignocaine; for urethral use; for external use in medicines containing 10% or less and more than 2%
96
Lindane; for external use in medicines containing 2% or less
97
Lithium; for dermal use in medicines containing 1% or less but more than 0.01%; except for dermal use in medicines containing 0.01% or less
98
Lobelia inflata; except in medicines for smoking or burning
99
Lobeline; except when in medicines for smoking or burning
100
Lodoxamide; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
101
Loperamide; in packs containing not more than 20 tablets or capsules; except in divided solid dosage forms for oral use containing 2 milligrams or less of loperamide per dosage form when sold in a pack containing not more than 8 dosage forms approved by the Minister or the Director-General for distribution as a general sales medicine for the symptomatic treatment of acute non-specific diarrhoea
102
Loratadine; for oral use; except in divided solid dosage forms for oral use containing 10 milligrams or less per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 10 days’ supply
103
Macrogols; in preparations for oral use as a liquid concentrate for laxative use
105
Meclozine; in a sealed container of not more than 12 tablets or capsules for the prevention or treatment of travel sickness except when sold at a transport terminal or aboard a ship or aircraft
106
Mefenamic acid; in solid dose form in packs containing not more than 30 tablets or capsules for the treatment of dysmenorrhoea
107
Mepyramine; for dermal use; except for external use in medicines containing 2% or less in packs not exceeding 25 grams
108
Mercuric oxide; for ophthalmic use
109
Mercurochrome; in preparations for external use containing 2% or less
110
Mercury; for external use in medicines containing 0.5% or less; except in medicines containing 1 milligram or less per litre or per kilogram
111
Methoxamine; for external use in medicines containing more than 1%; except for external use in medicines containing 1% or less
114
Miconazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
115
Minoxidil; for dermal use in medicines containing 5% or less
116
Mometasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 200 micrograms (as a single dose) in a pack containing 200 actuations or less
117
Morphine; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
118
Naphazoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
119
Naproxen; in solid dose form containing 250 milligrams or less per dose form in packs of not more than 30 tablets or capsules
121
Nicotine; for inhalation except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner, nurse, pharmacist, or psychologist
122
Nizatidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply
124
Nystatin; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
125
Omeprazole; in divided solid dosage forms for oral use containing 20 milligrams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units
126
Opium; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
127
Oxetacaine; for internal use
128
Oxiconazole; for dermal use except in medicines for tinea pedis only
129
Oxymetazoline; except for nasal use when sold at an airport; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except for nasal use in medicines containing 0.05% or less when sold in the manufacturer’s original pack with a pack size of 20 millilitres or less
130
Pantoprazole; in divided solid dosage forms for oral use containing 20 milligrams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units
131
Papaverine; except for injection
132
Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in slow-release forms containing 665 milligrams or less and more than 500 milligrams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams
133
Paraformaldehyde; except in medicines containing 5% or less
134
Penciclovir; for external use for the treatment of herpes labialis; except in medicines for external use containing 1% or less in a pack containing 10 grams or less for the treatment of herpes labialis
136
Phenazone; for external use
137
Pheniramine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing pheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
138
Phenol; except in medicines other than for injection containing 3% or less
139
Phenylephrine; for nasal use in medicines containing more than 1%; for ophthalmic use in medicines containing 5% or less and more than 1%; for oral use in medicines containing more than 50 milligrams per recommended daily dose or in packs containing more than 250 milligrams of phenylephrine per pack; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years; except for nasal or ophthalmic use in medicines containing 1% or less; except for oral use in medicines containing 50 milligrams or less per recommended daily dose and in packs containing 250 milligrams or less of phenylephrine per pack
140
Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
142
Podophyllotoxin; for external use for the treatment of warts other than anogenital warts in medicines containing 0.5% or less; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
143
Podophyllum emodi; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
144
Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
145
Potassium; for internal use: in slow-release or enteric coated forms; except for internal use: in medicines containing 100 milligrams or less per recommended dose; in medicines containing more than 100 milligrams per recommended dose except in medicines for oral rehydration therapy, parenteral nutrition replacement, or dialysis; except in glucosamine sulphate complexed products containing 600 milligrams or less of potassium chloride per recommended dose; except for external use
146
Potassium chlorate; except in medicines containing 10% or less
147
Prilocaine; for dermal use in medicines containing 10% or less of local anaesthetic substances
148
Procyclidine; for dermal use in medicines containing 5% or less
149
Promethazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing promethazine or when at least 1 of the other active ingredients is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft
150
Propamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
152
Pyrethrins; except in medicines containing 10% or less
153
Pyrithione zinc; except in medicines for treatment of the scalp containing 2% or less
154
Ranitidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner when sold in the manufacturer’s original pack containing not more than 14 days’ supply; except in medicines containing 300 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply
156
Selenium; for oral use in medicines containing 300 micrograms or less and more than 150 micrograms per recommended daily dose; for external use except in medicines containing 3.5% or less of selenium sulphide
158
Silver; except in oral solutions containing 0.3% or less or other medicines containing 1% or less
159
Silver sulfadiazine; for external use in pack sizes of 50 grams or less
160
Sodium cromoglycate; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
161
Sodium nitrite; except for use as an excipient
162
Sodium picosulphate; in oral laxative preparations
163
Squill; except in medicines containing 1% or less
164
Stramonium; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
165
Sulconazole; for dermal use
166
Sulfadiazine, silver; for external use in pack sizes of 50 grams or less
167
Terbinafine; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
169
Tetrahydrozoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
171
Tioconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
173
Triamcinolone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age and when in aqueous nasal sprays delivering up to 55 micrograms per actuation when the maximum recommended daily dose is no greater than 220 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine
174
Trimeprazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing trimeprazine or when at least 1 of the other therapeutically active ingredients is a sympathomimetic decongestant
175
Triprolidine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing triprolidine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
178
Xylenols; except in medicines containing 3% or less
179
Xylometazoline; except for nasal use when sold at an airport; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
180
Zinc chloride; for dermal use in medicines containing more than 5%